Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Unlike traditional pain management, ARA-290 activates your body's innate repair receptor to reduce chronic inflammation, support small nerve fiber regeneration, and improve microvascular function without stimulating red blood cell production
State Medicaid programs will also have access to these medications at these prices. CNBC reported on November 6, 2025, that Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. A senior administration official explained the rationale to CNBC: We are constraining the access for patients that will benefit clinically from it, weve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically. Documentation of these qualifying conditions will be essential for coverage approval
And yet, they have different approved uses
However, evidence on the cardiovascular benefits of tirzepatide is only emerging and no randomized study has directly compared it to semaglutide 16,17
US$ 23.93
US$ 24.79
US$ 29.27
US$ 27.81
US$ 26.89
US$ 20.56
